» Articles » PMID: 35155258

Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Abstract

Lung cancer is the second cause of cancer related deaths worldwide. Chemotherapy and immunotherapy represent the current standard of care for advanced NSCLC. Platinum-based chemotherapy expands late-differentiated T cell populations. Therefore, immune restoration after chemotherapy to adjuvate the immunotherapeutic potential could be crucial. The aim of this study was to evaluate the effect of Biomodulina T (BT), a thymic polypeptide fraction, on peripheral lymphocytes subpopulations in the context of cancer disease. Additionally, whether these effects might induce a better response to CIMAvax-EGF, an epidermal growth factor (EGF) depleting immunotherapy. Eighteen advanced NSCLC patients were evaluated after being treated with platinum-based chemotherapy. We found that the frequency of terminally differentiated effector T cells re-expressing CD45RA (EMRA) CD4+ (p=0.0031) and CD8+ (p=0.0372) T cells decreased with the administration of BT, whereas CD4+ naive T cells increase in more than 70% of the patients. Remarkably, CD4+ and CD8+ T lymphocytes expressing programmed cell death receptor-1 (PD1) significantly decreased after BT administration (p=0.0005 and p<0.0001, respectively). We also found an enhancement of the anti-EGF antibody response with a large percentage of patients treated with CIMAvax-EGF reaching the good antibody response condition after four vaccine doses. Moreover, the median overall survival of patients treated with CIMAvax-EGF was 16.09 months. In conclusion, our results suggest that the immunorestoration generated by the administration of BT after first-line chemotherapy may induce a better immune response to CIMAvax-EGF that could translate into the clinical benefit of patients diagnosed with advanced NSCLC.

Citing Articles

Aging and chronic inflammation: highlights from a multidisciplinary workshop.

Saavedra D, Ane-Kouri A, Barzilai N, Caruso C, Cho K, Fontana L Immun Ageing. 2023; 20(1):25.

PMID: 37291596 PMC: 10248980. DOI: 10.1186/s12979-023-00352-w.


Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events.

Muller B, Barenwaldt A, Herzig P, Zippelius A, Maul L, Hess V Front Immunol. 2023; 14:1125111.

PMID: 37122748 PMC: 10130408. DOI: 10.3389/fimmu.2023.1125111.

References
1.
Hall R, Gray J, Chiappori A . Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control. 2013; 20(1):22-31. DOI: 10.1177/107327481302000105. View

2.
Arrieta O, Barron F, Ramirez-Tirado L, Zatarain-Barron Z, Cardona A, Diaz-Garcia D . Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020; 6(6):856-864. PMC: 7290397. DOI: 10.1001/jamaoncol.2020.0409. View

3.
Crombet Ramos T, Santos Morales O, Dy G, Leon Monzon K, Lage Davila A . The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. Front Oncol. 2021; 11:639745. PMC: 8240591. DOI: 10.3389/fonc.2021.639745. View

4.
Ottonello S, Genova C, Cossu I, Fontana V, Rijavec E, Rossi G . Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. Front Immunol. 2020; 11:125. PMC: 7018763. DOI: 10.3389/fimmu.2020.00125. View

5.
Castells Martinez E, Del Valle R, Gonzalez E, Melchor A, Perez P, Gonzalez I . An enzyme immunoassay for determining epidermal growth factor (EGF) in human serum samples using an ultramicroanalytical system. J Immunoassay Immunochem. 2016; 38(2):190-201. DOI: 10.1080/15321819.2016.1236729. View